Yj. Gu et al., CLOTTING AND FIBRINOLYTIC DISTURBANCE DURING LUNG TRANSPLANTATION - EFFECT OF LOW-DOSE APROTININ, Journal of thoracic and cardiovascular surgery, 112(3), 1996, pp. 599-606
Patients undergoing lung transplantation are often confronted,vith a b
leeding problem that may be due in part to the use of cardiopulmonary
bypass and its activation of blood clotting and fibrinolysis. Objectiv
e: We performed a prospective study to determine whether and to what e
xtent the clotting and fibrinolytic systems are being activated and wh
ether low-dose aprotinin is effective in inhibiting blood activation d
uring lung transplantation. Methods: Thirty lung transplantations perf
ormed on 29 patients were divided into a group with cardiopulmonary by
pass alone (n = 12), a group with cardiopulmonary bypass and 2 x 10(6)
KIL aprotinin administered at the beginning of bypass in the pump pri
me (n = 12), and a group without cardiopulmonary bypass (n = 6), Seria
l blood samples were taken from the recipient before anesthesia, seven
times during the operation, and 4 and 24 hours thereafter, Results: R
esults show that in the group having cardiopulmonary bypass alone, the
concentration of the clotting marker thrombin/antithrombin III comple
x increased significantly during the early phase of the operation (p <
0.01) and remained high until the end of the operation, Levels of tis
sue-type plasminogen activator, a trigger of fibrinolysis released by
injured endothelium, also increased sharply in the early phase of the
operation in the cardiopulmonary bypass group (p < 0.01), followed by
a significant increase in fibrin degradation products (p < 0.01), In t
he aprotinin group, a significant reduction of thrombin/antithrombin I
II complex (p < 0.05), tissue-type plasminogen activator (p < 0.05), a
nd fibrin degradation products (p < 0.05) was observed in the early ph
ase of the operation compared with levels in the bypass group, but the
se markers increased late during bypass associated with a significant
drop (p < 0.05) of plasma aprotinin level monitored by plasmin inhibit
ing capacity, In the nonbypass group, concentrations of thrombin/antit
hrombin III complex and tissue-type plasminogen activator also rose si
gnificantly (p < 0.05) in the early phase of the operation, but the le
vels were significantly lower than those of the bypass group (p < 0.05
), Blood loss during the operation was 2521 +/- 550 mi in the bypass g
roup, 1991 +/- 408 mi in the aprotinin/bypass group, and 875 +/- 248 m
i in the nonbypass group, Conclusion: These results suggest that clott
ing and fibrinolysis are activated during lung transplantation, especi
ally in patients undergoing cardiopulmonary bypass. Aprotinin in a low
dose significantly reduced activation of clotting and fibrinolysis in
the early phase of the operation but not during the late phase of lun
g transplantation.